Premium
The plot thickens while the scope broadens: a holistic view on IL ‐17 in psoriasis and other inflammatory disorders
Author(s) -
Schön Michael P.
Publication year - 2014
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/exd.12541
Subject(s) - secukinumab , psoriasis , ixekizumab , interleukin 17 , immunology , cytokine , disease , monoclonal antibody , thymic stromal lymphopoietin , medicine , psoriatic arthritis , antibody , pathology
Psoriasis is an instructive example highlighting our growing knowledge about pathophysiological functions of interleukin ( IL )‐17. IL ‐17A is the predominant isoform implicated in key pathogenic features in this and other chronic inflammatory disorders. Several monoclonal antibodies targeting IL ‐17A (secukinumab, ixekizumab) or its IL ‐17 RC / RA receptor (brodalumab) are currently in late stages of clinical development, where they have shown impressive efficacy. While the eponymous IL ‐17 has been thought to originate primarily from T helper (Th)17 cells, more recent investigations by several groups suggest that other cell types in psoriatic lesions, such as neutrophils and mast cells, are rich sources of IL ‐17, thus presumably contributing to the disease process to an as yet underestimated extent. This recent paradigm shift provides a plausible explanation for the rapid and strong efficacy of the novel compounds targeting IL ‐17 functions in psoriasis and other inflammatory disorders, and provide a more comprehensive view on the complex cytokine network in these conditions.